BRAF is altered in 35.7% of melanoma patients with BRAF Codon 600 Missense present in 25.52% of all melanoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 42 clinical trials for melanoma, of which 22 are open and 20 are closed. Of the trials that contain BRAF Codon 600 Missense and melanoma as inclusion criteria, 2 are early phase 1 (2 open), 9 are phase 1 (3 open), 4 are phase 1/phase 2 (1 open), 24 are phase 2 (13 open), and 3 are phase 3 (3 open) [5].

Atezolizumab, cobimetinib, vemurafenib, dabrafenib, pembrolizumab, trametinib, and encorafenib have evidence of efficacy in patients with BRAF Codon 600 Missense in melanoma [5].

BRAF is altered in 18.75% of Erdheim-Chester disease patients with BRAF Codon 600 Missense present in 15.62% of all Erdheim-Chester disease patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for Erdheim-Chester disease, of which 0 are open and 1 is closed. Of the trial that contains BRAF Codon 600 Missense and Erdheim-Chester disease as inclusion criteria, 1 is phase 2 (0 open) [5].

Vemurafenib has evidence of efficacy in patients with BRAF Codon 600 Missense in Erdheim-Chester disease [5].

BRAF is altered in 6.59% of malignant solid tumor patients with BRAF Codon 600 Missense present in 3.54% of all malignant solid tumor patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 20 clinical trials for malignant solid tumor, of which 13 are open and 7 are closed. Of the trials that contain BRAF Codon 600 Missense and malignant solid tumor as inclusion criteria, 10 are phase 1 (5 open), 4 are phase 1/phase 2 (3 open), and 6 are phase 2 (5 open) [5].

BRAF is altered in 5.15% of non-small cell lung carcinoma patients with BRAF Codon 600 Missense present in 1.4% of all non-small cell lung carcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 7 are open and 1 is closed. Of the trials that contain BRAF Codon 600 Missense and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 5 are phase 2 (5 open) [5].

BRAF is altered in 11.2% of colorectal carcinoma patients with BRAF Codon 600 Missense present in 7.91% of all colorectal carcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 5 clinical trials for colorectal carcinoma, of which 1 is open and 4 are closed. Of the trials that contain BRAF Codon 600 Missense and colorectal carcinoma as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (0 open) [5].

BRAF is altered in 41.18% of cutaneous melanoma patients with BRAF Codon 600 Missense present in 29.29% of all cutaneous melanoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 4 clinical trials for cutaneous melanoma, of which 3 are open and 1 is closed. Of the trials that contain BRAF Codon 600 Missense and cutaneous melanoma as inclusion criteria, 4 are phase 2 (3 open) [5].

BRAF is altered in 8.47% of glioma patients with BRAF Codon 600 Missense present in 3.97% of all glioma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 4 clinical trials for glioma, of which 2 are open and 2 are closed. Of the trials that contain BRAF Codon 600 Missense and glioma as inclusion criteria, 3 are phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

BRAF is altered in 4.05% of multiple myeloma patients with BRAF Codon 600 Missense present in 3.24% of all multiple myeloma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 4 clinical trials for multiple myeloma, of which 3 are open and 1 is closed. Of the trials that contain BRAF Codon 600 Missense and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (2 open) [5].

BRAF is altered in 66.54% of thyroid gland papillary carcinoma patients with BRAF Codon 600 Missense present in 63.42% of all thyroid gland papillary carcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 3 clinical trials for thyroid gland papillary carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRAF Codon 600 Missense and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

BRAF is altered in 50.55% of thyroid gland adenocarcinoma patients with BRAF Codon 600 Missense present in 47.78% of all thyroid gland adenocarcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 2 clinical trials for thyroid gland adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRAF Codon 600 Missense and thyroid gland adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is no phase specified (1 open) [5].

BRAF is altered in 48.42% of langerhans cell histiocytosis patients with BRAF Codon 600 Missense present in 40.0% of all langerhans cell histiocytosis patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 2 clinical trials for langerhans cell histiocytosis, of which 1 is open and 1 is closed. Of the trials that contain BRAF Codon 600 Missense and langerhans cell histiocytosis as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [5].

BRAF is altered in 48.4% of melanoma of unknown primary patients with BRAF Codon 600 Missense present in 32.8% of all melanoma of unknown primary patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 2 clinical trials for melanoma of unknown primary, of which 1 is open and 1 is closed. Of the trials that contain BRAF Codon 600 Missense and melanoma of unknown primary as inclusion criteria, 2 are phase 2 (1 open) [5].

BRAF is altered in 18.56% of poorly differentiated thyroid gland carcinoma patients with BRAF Codon 600 Missense present in 15.57% of all poorly differentiated thyroid gland carcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 2 clinical trials for poorly differentiated thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF Codon 600 Missense and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

BRAF is altered in 11.36% of mucosal melanoma patients with BRAF Codon 600 Missense present in 5.11% of all mucosal melanoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 2 clinical trials for mucosal melanoma, of which 1 is open and 1 is closed. Of the trials that contain BRAF Codon 600 Missense and mucosal melanoma as inclusion criteria, 2 are phase 2 (1 open) [5].

BRAF is altered in 4.62% of bladder carcinoma patients with BRAF Codon 600 Missense present in 0.23% of all bladder carcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF Codon 600 Missense and bladder carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

BRAF is altered in 2.33% of non-hodgkin lymphoma patients with BRAF Codon 600 Missense present in 0.19% of all non-hodgkin lymphoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF Codon 600 Missense and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

BRAF is altered in 0.76% of thyroid gland follicular carcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 2 clinical trials for thyroid gland follicular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF Codon 600 Missense and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

BRAF is altered in 76.19% of anaplastic pleomorphic xanthoastrocytoma patients with BRAF Codon 600 Missense present in 71.43% of all anaplastic pleomorphic xanthoastrocytoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 71.05% of hairy cell leukemia patients with BRAF Codon 600 Missense present in 71.05% of all hairy cell leukemia patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for hairy cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and hairy cell leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 43.3% of thyroid gland carcinoma patients with BRAF Codon 600 Missense present in 40.99% of all thyroid gland carcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 40.0% of anaplastic ganglioglioma patients with BRAF Codon 600 Missense present in 30.0% of all anaplastic ganglioglioma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for anaplastic ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and anaplastic ganglioglioma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 25.0% of histiocytic sarcoma patients with BRAF Codon 600 Missense present in 25.0% of all histiocytic sarcoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for histiocytic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and histiocytic sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 11.13% of colorectal adenocarcinoma patients with BRAF Codon 600 Missense present in 7.81% of all colorectal adenocarcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 7.92% of malignant central nervous system neoplasm patients with BRAF Codon 600 Missense present in 3.67% of all malignant central nervous system neoplasm patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 6.45% of solid neoplasm patients with BRAF Codon 600 Missense present in 3.45% of all solid neoplasm patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for solid neoplasm, of which 0 are open and 1 is closed. Of the trial that contains BRAF Codon 600 Missense and solid neoplasm as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

BRAF is altered in 6.15% of cancer patients with BRAF Codon 600 Missense present in 3.29% of all cancer patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains BRAF Codon 600 Missense and cancer as inclusion criteria, 1 is phase 1 (0 open) [5].

BRAF is altered in 5.78% of primary brain neoplasm patients with BRAF Codon 600 Missense present in 2.43% of all primary brain neoplasm patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for primary brain neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and primary brain neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

BRAF is altered in 4.41% of malignant glioma patients with BRAF Codon 600 Missense present in 2.16% of all malignant glioma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and malignant glioma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 5.02% of cholangiocarcinoma patients with BRAF Codon 600 Missense present in 1.67% of all cholangiocarcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 5.51% of non-squamous non-small cell lung carcinoma patients with BRAF Codon 600 Missense present in 1.56% of all non-squamous non-small cell lung carcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 4.57% of biliary tract carcinoma patients with BRAF Codon 600 Missense present in 1.4% of all biliary tract carcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 2.24% of ovarian carcinoma patients with BRAF Codon 600 Missense present in 0.77% of all ovarian carcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 0.64% of gastrointestinal stromal tumor patients with BRAF Codon 600 Missense present in 0.53% of all gastrointestinal stromal tumor patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 2.49% of pancreatic carcinoma patients with BRAF Codon 600 Missense present in 0.45% of all pancreatic carcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 1.55% of malignant salivary gland neoplasm patients with BRAF Codon 600 Missense present in 0.42% of all malignant salivary gland neoplasm patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 2.65% of B-cell non-hodgkin lymphoma patients with BRAF Codon 600 Missense present in 0.26% of all B-cell non-hodgkin lymphoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 1.85% of squamous cell lung carcinoma patients with BRAF Codon 600 Missense present in 0.08% of all squamous cell lung carcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF is altered in 2.86% of prostate carcinoma patients with BRAF Codon 600 Missense present in 0.03% of all prostate carcinoma patients [4].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for juvenile xanthogranuloma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and juvenile xanthogranuloma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for metastatic malignant neoplasm in the brain, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and metastatic malignant neoplasm in the brain as inclusion criteria, 1 is phase 2 (1 open) [5].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for neurofibroma, of which 0 are open and 1 is closed. Of the trial that contains BRAF Codon 600 Missense and neurofibroma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

BRAF Codon 600 Missense is an inclusion criterion in 1 clinical trial for splenic diffuse red pulp small B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF Codon 600 Missense and splenic diffuse red pulp small B-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].